Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

PMPA: GILD began enrollment of up to 175 HIV-positive patients in a double-blind, placebo-controlled, dose-ranging Phase II trial.

September 8, 1998 7:00 AM UTC

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: PMPA oral prodrug Indication: Treat HIV infection Status: GILD began enrollment of up to 175 HIV-positive patients in a double-blind, placebo...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article